Literature DB >> 26895511

CD4+ and CD8+ CD28(null) T Cells Are Cytotoxic to Autologous Muscle Cells in Patients With Polymyositis.

Jayesh M Pandya1, Paulius Venalis1, Lubna Al-Khalili2, Mohammad Shahadat Hossain1, Vanessa Stache1, Ingrid E Lundberg1, Vivianne Malmström1, Andreas E R Fasth3.   

Abstract

OBJECTIVE: Inflammatory T cell infiltrates in the skeletal muscle tissue of patients with polymyositis are dominated by CD28-negative effector (CD28(null) ) T cells of both the CD4 and CD8 lineage. These cells are potentially cytotoxic, and the aim of the present study was to develop a fully autologous cell culture system in which to investigate the functional contribution of such CD28(null) T cells to myotoxicity.
METHODS: In vitro cocultures of autologous skeletal muscle cells and T cell subsets obtained from 5 polymyositis patients were performed. Myotoxicity of T cells was quantified by calcein release and flow cytometric analyses. T cell degranulation was blocked with concanamycin A. Specific blocking of perforin, cytokines, and HLA was performed using antibodies.
RESULTS: Both CD4+CD28(null) and CD8+CD28(null) T cells induced more muscle cell death than did their CD28+ counterparts. Differentiated muscle cells (myotubes) were more sensitive to T cell-mediated cell death than were their precursors (myoblasts). Both CD8+ and CD4+ CD28(null) T cells displayed perforin polarization toward muscle cells and secreted higher levels of granzyme B and interferon-γ (IFNγ) in coculture than did CD28+ T cells. The myotoxic effects of CD28(null) T cells were reduced upon the blocking of perforin, cytokines, and HLA. Addition of IFNγ or tumor necrosis factor did not induce skeletal muscle cell death in the absence of T cells; however, it did up-regulate HLA expression on muscle cells.
CONCLUSION: Myotoxicity of CD4+ and CD8+ CD28(null) T cells is mediated by directed perforin-dependent killing and can be further influenced by IFNγ-induced HLA expression on muscle cells. The data suggest that CD28(null) T cells are key effector cells that contribute to the muscle cell damage in polymyositis.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26895511     DOI: 10.1002/art.39650

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  12 in total

Review 1.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

2.  Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy.

Authors:  Felicitas Escher; Uwe Kühl; Dirk Lassner; Wolfgang Poller; Dirk Westermann; Burkert Pieske; Carsten Tschöpe; Heinz-Peter Schultheiss
Journal:  Clin Res Cardiol       Date:  2016-06-16       Impact factor: 5.460

3.  Toll-Like Receptor 4-Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Inflammatory Development of Polymyositis by Mediating Interferon-γ and Interleukin-17A in Humans and Experimental Autoimmune Myositis Mouse Model.

Authors:  Hongya Zhang; Fangyuan He; Ming Shi; Wenxiu Wang; Xiaojia Tian; Juan Kang; Wenjuan Han; Rui Wu; Linfu Zhou; Mengmeng Hu; Xiaobo Li; Fang Mi; Gang Zhao; Hongge Jia
Journal:  Front Neurol       Date:  2017-04-12       Impact factor: 4.003

4.  T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients.

Authors:  Miranda Houtman; Louise Ekholm; Espen Hesselberg; Karine Chemin; Vivianne Malmström; Ann M Reed; Ingrid E Lundberg; Leonid Padyukov
Journal:  Arthritis Res Ther       Date:  2018-08-29       Impact factor: 5.156

5.  The immune system in sporadic inclusion body myositis patients is not compromised by blood-flow restricted exercise training.

Authors:  Kasper Yde Jensen; Mikkel Jacobsen; Henrik Daa Schrøder; Per Aagaard; Jakob Lindberg Nielsen; Anders Nørkær Jørgensen; Eleanor Boyle; Rune Dueholm Bech; Sofie Rosmark; Louise Pyndt Diederichsen; Ulrik Frandsen
Journal:  Arthritis Res Ther       Date:  2019-12-18       Impact factor: 5.156

6.  A new in vitro model of polymyositis reveals CD8+ T cell invasion into muscle cells and its cytotoxic role.

Authors:  Mari Kamiya; Fumitaka Mizoguchi; Akito Takamura; Naoki Kimura; Kimito Kawahata; Hitoshi Kohsaka
Journal:  Rheumatology (Oxford)       Date:  2020-01-01       Impact factor: 7.580

Review 7.  The Evolution of Complex Muscle Cell In Vitro Models to Study Pathomechanisms and Drug Development of Neuromuscular Disease.

Authors:  Jana Zschüntzsch; Stefanie Meyer; Mina Shahriyari; Karsten Kummer; Matthias Schmidt; Susann Kummer; Malte Tiburcy
Journal:  Cells       Date:  2022-04-05       Impact factor: 6.600

Review 8.  Programmed Cell Death Pathways in the Pathogenesis of Idiopathic Inflammatory Myopathies.

Authors:  Jia Shi; Mingwei Tang; Shuang Zhou; Dong Xu; Jiuliang Zhao; Chanyuan Wu; Qian Wang; Xinping Tian; Mengtao Li; Xiaofeng Zeng
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

9.  Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis.

Authors:  Jayesh M Pandya; Ingela Loell; Mohammad Shahadat Hossain; Mei Zong; Helene Alexanderson; Sukanya Raghavan; Ingrid E Lundberg; Vivianne Malmström
Journal:  Arthritis Res Ther       Date:  2016-04-01       Impact factor: 5.156

10.  Immunohistochemical phenotyping of T cells, granulocytes, and phagocytes in the muscle of cancer patients: association with radiologically defined muscle mass and gene expression.

Authors:  Ana Anoveros-Barrera; Amritpal S Bhullar; Cynthia Stretch; Abha R Dunichand-Hoedl; Karen J B Martins; Aja Rieger; David Bigam; Todd McMullen; Oliver F Bathe; Charles T Putman; Catherine J Field; Vickie E Baracos; Vera C Mazurak
Journal:  Skelet Muscle       Date:  2019-09-14       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.